Tier 2 — strong

Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition

D R Ferry, A Smith, J Malkhandi, D W Fyfe, P G deTakats, D Anderson, J Baker, D J Kerr
Clinical cancer research : an official journal of the American Association for Cancer Research 1996 2(4):659-68

Bibliography

PubMed
PMID 9816216
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignPhase 1 intravenous oncology dose-escalation study
ModelHuman intervention research
SamplePatients with cancer; multiple dose cohorts, total sample not stated in the indexed abstract
InterventionIntravenous quercetin 60–1,700 mg/m² on weekly or three-weekly schedules
DurationDose-escalation treatment courses
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 1996, this source examined kidney and cancer research. Design: Phase 1 intravenous oncology dose-escalation study. Sample/model: Patients with cancer; multiple dose cohorts, total sample not stated in the indexed abstract. The exposure or intervention was Intravenous quercetin 60–1,700 mg/m² on weekly or three-weekly schedules. Follow-up or treatment period: Dose-escalation treatment courses.

Tyrosine-phosphorylation inhibition was observed, and renal toxicity became dose limiting at high intravenous exposure.

Experimental intravenous oncology treatment is not oral supplementation. Individual tumor-marker changes do not establish anticancer efficacy, and intravenous doses must not be converted into consumer regimens.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Tyrosine-phosphorylation inhibition was observed, and renal toxicity became dose limiting at high intravenous exposure.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Intravenous quercetin 60–1,700 mg/m² on weekly or three-weekly schedules; Dose-escalation treatment courses.

What this study can and cannot tell us

  • Experimental intravenous oncology treatment is not oral supplementation. Individual tumor-marker changes do not establish anticancer efficacy, and intravenous doses must not be converted into consumer regimens.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis
Marcia Cruz-Correa et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2006

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology